Spyre Therapeutics (SYRE) Other Gross PP&E Adjustments (2016 - 2025)
Spyre Therapeutics' Other Gross PP&E Adjustments history spans 11 years, with the latest figure at -$12.9 million for Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 81.94% year-over-year to -$12.9 million; the TTM value through Dec 2025 reached -$12.9 million, down 81.94%, while the annual FY2025 figure was -$12.9 million, 81.94% down from the prior year.
- Other Gross PP&E Adjustments reached -$12.9 million in Q4 2025 per SYRE's latest filing, down from -$7.1 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $778000.0 in Q4 2021 to a low of -$12.9 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 5 years is -$5.0 million, with a median of -$5.3 million recorded in 2021.
- The largest YoY upside for Other Gross PP&E Adjustments was 34.28% in 2023 against a maximum downside of 762.4% in 2023.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $778000.0 in 2021, then dropped by 17.61% to $641000.0 in 2022, then tumbled by 762.4% to -$4.2 million in 2023, then plummeted by 67.55% to -$7.1 million in 2024, then tumbled by 81.94% to -$12.9 million in 2025.
- Per Business Quant, the three most recent readings for SYRE's Other Gross PP&E Adjustments are -$12.9 million (Q4 2025), -$7.1 million (Q4 2024), and -$4.2 million (Q4 2023).